CTOs on the Move

Chroma Medicine

www.chromamedicine.com

 
Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Alliance Analytical

Alliance Analytical is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Augustine Biomedical Design

Augustine Biomedical Design is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`

Faze Medicines

Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.

Caladrius

Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.